Valuation: Phytopharm plc

Market Cap 1.7Cr 2.25Cr 2.01Cr 1.87Cr 3.2Cr 217.34Cr 3.22Cr 22Cr 8.8Cr 110.81Cr 8.43Cr 8.25Cr 355.59Cr P/E 2026 *
-5.54x
P/E 2027 * -5.96x
Enterprise Value 67.71L 89.59L 80.02L 74.44L 1.28Cr 87Cr 1.28Cr 8.96Cr 3.51Cr 44Cr 3.36Cr 3.29Cr 141.86Cr EV / Sales 2026 *
0.85x
EV / Sales 2027 * 1.21x
Free-Float
89.57%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 53 19/08/2024
Director of Finance/CFO 50 21/08/2019
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Chairman 51 -
Director/Board Member 50 21/08/2019
Director/Board Member 60 21/01/2022
Change 5-day change 1-year change 3-year change Capi.($)
-2.59%-5.70%+40.86%+83.11% 7.21TCr
+3.23%-10.67%+4.87%+55.97% 4.94TCr
+1.56%+2.07%+5.03%+33.38% 4.72TCr
+0.87%-8.17%+298.53%+645.03% 4.03TCr
+0.39%+0.65%+28.02%+30.24% 4.26TCr
+1.24%-1.01%+5.56%+105.14% 3.98TCr
-2.13%-2.18%+7.51%+50.31% 3.05TCr
+5.32%+0.06%-7.20%-11.30% 2.31TCr
+3.78%+5.71%+16.43%-1.77% 2.11TCr
Average +1.30%-3.91%+44.40%+110.01% 4.07TCr
Weighted average by Cap. +0.78%-4.28%+47.20%+117.56%

Financials

2026 *2027 *
Net sales 80L 1.06Cr 94.55L 87.95L 1.51Cr 102.46Cr 1.52Cr 11Cr 4.15Cr 52Cr 3.98Cr 3.89Cr 167.63Cr 90L 1.19Cr 1.06Cr 98.95L 1.7Cr 115.26Cr 1.71Cr 12Cr 4.67Cr 59Cr 4.47Cr 4.37Cr 188.58Cr
Net income -21.43L -28.36L -25.33L -23.56L -40.46L -27Cr -40.64L -2.84Cr -1.11Cr -14Cr -1.06Cr -1.04Cr -45Cr -28.01L -37.07L -33.1L -30.79L -52.89L -36Cr -53.11L -3.71Cr -1.45Cr -18Cr -1.39Cr -1.36Cr -59Cr
Net Debt -1.02Cr -1.35Cr -1.21Cr -1.12Cr -1.93Cr -130.63Cr -1.93Cr -13Cr -5.29Cr -67Cr -5.07Cr -4.96Cr -213.72Cr -61L -80.72L -72.09L -67.06L -1.15Cr -78Cr -1.16Cr -8.07Cr -3.16Cr -40Cr -3.03Cr -2.96Cr -127.81Cr
Logo Phytopharm plc
IXICO plc is engaged in neuroscience imaging and biomarker analytics, using its artificial intelligence (AI)-driven platform to help advance drug development in neurological disorders. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Alzheimer's disease, Parkinson's disease and Huntington's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include imaging biomarkers, trial management, data analytics, consultancy and post-marketing surveillance. Its TrialTracker platform provides a standardized, compliant and efficient workflow for capturing visual read results of MRI, SPECT, PET and CT scans, supporting single, over-read and double adjudicated read paradigms.
Employees
-
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Ratings Surperformance© - Phytopharm plc